Role of lipoproteins and proprotein convertase subtilisin/kexin type 9 in endotoxin clearance in sepsis.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and human genetic association studies
PubMed 27552305 · doi:10.1097/MCC.0000000000000351
What was done
Narrative review evaluating preclinical evidence and human genetic data on the role of proprotein convertase subtilisin/kexin type 9 (PCSK9), lipoproteins, and low-density lipoprotein (LDL) receptors in clearing pathogen lipids (such as lipopolysaccharide and lipoteichoic acid) during sepsis.
What was found
The abstract reports no quantitative values or effect estimates. Qualitatively, PCSK9 decreases hepatocyte LDL receptors, thereby reducing the clearance of lipoprotein-bound pathogen lipids. Preclinical reduction or inhibition of PCSK9 in septic mice increased lipopolysaccharide clearance, attenuated inflammatory responses, and improved survival. Similarly, humans with loss-of-function variants in the PCSK9 gene exhibit increased survival in sepsis.
Why it matters
Highlights a biological overlap between lipid transport and innate pathogen clearance, supporting further evaluation of PCSK9 inhibitors as therapeutic agents to improve endotoxin removal in sepsis.
Limits
The abstract provides no original clinical trial data, quantitative metrics, or sample sizes. Human evidence summarized is limited to genetic association studies, and interventional clinical efficacy of PCSK9 inhibition remains unestablished in this record.
Cited by
- supports Increasing LDL receptor activity and hepatic LDL clearance from the blood lowers circulating lipopolysaccharide (LPS) levels.